Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.

Everolimus, letrozole, metformin: Triple threat against recurrent endometrial cancer

04 Mar 2020

The combination of metformin, everolimus and letrozole has demonstrated clinical activity in patients with recurrent endometrioid endometrial cancer (EEC), inducing better response in those with progesterone receptor (PgR)-positive tumours, according to the results of a phase II study.

The trial included 62 women (median age, 62 years; median body mass index, 33.3 kg/m2) with ≤2 prior chemotherapy regimens for recurrence. Majority of them (93 percent) had pure endometrioid histology; 85 percent had received at least one prior chemotherapy agent for recurrence, while 65 percent had received prior radiotherapy.

All patients underwent pretreatment biopsy, followed by everolimus 10 mg, letrozole 2.5 mg and metformin 500 mg, all of which were administered orally twice a day on a 4-week cycle. Treatment was given until progression or toxicity. Only 54 patients were evaluable for response, with 401 cycles completed (median, 6 cycles). Thirteen patients received >12 cycles.

Twenty-seven patients achieved the primary endpoint of clinical benefit (defined as complete response, partial response [PR] or stable disease [SD]) at week 16, yielding a rate of 50 percent. Best overall response was PR, which was observed in 15 patients (28 percent); twelve patients (22 percent) had SD. The median follow-up was 17.9 months.

Median progression-free survival was 5.7 months, while median overall survival was 19.6 months. Response was notably more favourable in the subgroup of patients with PgR-positive disease (clinical benefit rate, 89.5 percent vs 27.3 percent; p=0.001).

The present data indicate that “the backbone of everolimus and letrozole are effective in treating women with recurrent EEC and may be a reasonable choice in second-line therapy,” researchers said. Also, the study provides evidence that the addition of metformin to the said combination is beneficial, without increasing toxicity for patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Dr Margaret Shi, 18 May 2020

A blood test is shown to be feasible and safe for early detection of multiple cancers in women with no current or known history of cancer, enabling early treatment with curative intent in a subset of individuals.

Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

Natalia Reoutova, 28 May 2020

Fasting-mimicking diet (FMD) cycles in combination with endocrine therapy (ET) cause metabolic changes in hormone receptor (HR)-positive breast cancer patients analogous to those observed in animal models, where they are associated with anticancer activity.